ReNeuron Group plc demonstrates key characteristics with its hepatocyte (liver) cell lines for drug discovery applications. 25/10/05

Guildford, UK, 25 October 2005: ReNeuron Group plc (LSE: RENE.L) today announced that it has developed human hepatocyte (liver) cell lines using its proprietary c-mycERTAM platform technology. These cell lines have been shown to express a range of adult human liver functional markers, indicating their potential value as a tool in assessing new drugs in terms of hepatic metabolism, enzyme induction and cellular toxicity.

More…

ReNeuron Group plc holds key meeting with the FDA regarding its ReN001 stem cell therapy for stroke. 22/09/05

Guildford, UK, 22 September 2005: ReNeuron Group plc (LSE: RENE.L) today announced that it has held a formal pre-IND1 meeting with the CBER2 component of the US Food & Drug Administration (FDA) regarding its lead ReN001 stem cell therapy to treat chronic disability after stroke.

More…

ReNeuron Group Plc Admission to Trading on AIM. 12/08/05

Guildford, UK, 12 August 2005: ReNeuron Group Plc (“ReNeuron” or the “Company”) announces that trading in the Company’s ordinary shares and warrants will commence today at 08:00 on London’s Alternative Investment Market (“AIM”), under the ticker symbols RENE.L’ and RENW.L’ respectively.

More…

ReNeuron Announces Successful Completion of Flotation. 05/08/05

Guildford, UK, 5 August 2005: ReNeuron Group plc (“ReNeuron” or the “Company”), the UK-based adult stem cell company, today announces that it has successfully completed its flotation on AIM (“Alternative Investment Market”).

More…

ReNeuron Announces Intention to List on AIM. 12/07/05

10 million placing to fund first human stem cell trial in major CNS disease

More…

ReNeuron enters stem cell cross-licence with StemCells, Inc.. 06/07/05

Guildford, Surrey, UK, July 6 2005: ReNeuron, the UK-based adult stem cell research and development company, announced today that it has entered into an agreement with StemCells, Inc. (NASDAQ: STEM), a leading US adult stem cell development company. The agreement gives StemCells exclusive access to ReNeuron’s proprietary c-mycER adult human stem cell immortalisation technology for use in the development of therapies for certain diseases targeted by StemCells, including lysosomal storage diseases, spinal cord injury, cerebral palsy and multiple sclerosis.

More…

ReNeuron comments on research highlighting contamination of certain stem cell lines. 26/01/05

ReNeuron, the UK-based stem cell research and development company, has noted the recent publication in Nature Medicine of findings by US researchers indicating that human embryonic stem cell lines (ESCs) have been contaminated by non-human molecules derived from the animal feeder cell layers used to grow the cells.

More…

ReNeuron consortium awarded UK grant for stem cell therapy development. 11/01/05

ReNeuron, the UK-based stem cell research and development company, is pleased to announce that a consortium led by it has been awarded a £2.2 million grant from the UK Department of Trade and Industry (DTI) under its Technology Programme.

More…

ReNeuron presents further pre-clinical stem cell data at US conference. 27/10/04

ReNeuron, the UK-based stem cell research and development company, is today presenting further pre-clinical efficacy data with its neural (brain) stem cell lines at the Society for Neuroscience 34th Annual Meeting (SfN) in San Diego, USA. Dr Kenny Pollock, ReNeuron’s Head of Stem Cell Biology, will give the platform presentation.

More…

ReNeuron business update and funding plans. 05/10/04

ReNeuron, the UK-based stem cell research and development company, is pleased to give an update on recent progress and future plans regarding its stem cell programmes. The Company is today separately announcing groundbreaking pre-clinical efficacy data with its ReN001 cell therapy programme for stroke. Based on this progress, the Company also announces its intention to seek further funding in order to progress its lead stem cell therapy programmes to the clinic.

More…